

**Table S1** Analysis of patients who filled in the HRQL questionnaires (responders) and those who did not (non-responders)

Characteristics	Responders (n=99)	Non-responders (n=30)	P value
Male sex	55 (56%)	17 (57%)	0.915
Age, years	63 (54–72)	71 (59–73)	0.075
Race			
Chinese	74 (75%)	24 (80%)	0.386
Malay	11 (11%)	2 (7%)	
Indian	8 (8%)	4 (13%)	
Others	6 (6%)	0	
Body mass index, kg/m <sup>2</sup>	24.3 (4.3)	24.6 (4.4)	0.768
Smoking history			
Never smoker	63 (64%)	21 (70%)	0.804
Ex-smoker	27 (27%)	7 (23%)	
Current smoker	9 (9%)	2 (7%)	
ILD diagnosis			
CTD-ILD	51 (51%)	16 (53%)	0.075
IPF	27 (27%)	3 (10%)	
Other ILDs	21 (21%)	11 (37%)	
Long term oxygen therapy use	7 (7%)	3 (10%)	0.697
mMRC score	1 (0–2)	1 (0–2)	0.984
CCI	3.0 (2.0–4.0)	3.5 (2.0–5.0)	0.069
Pulmonary hypertension	14 (14%)	6 (20%)	0.437
History of psychiatric disorder	4 (4%)	0	0.573
GAP index <sup>†</sup>			
Stage I	63 (64%)	11 (37%)	0.051
Stage II	24 (24%)	14 (47%)	
Stage III	7 (7%)	2 (7%)	
FVC <sup>‡</sup> (absolute, litres)	2.31 (0.73)	2.03 (0.74)	0.076
FVC <sup>‡</sup> (% predicted)	79.8 (21.6)	72.7 (23.5)	0.137
DLCO <sup>§</sup> (absolute, litres)	4.40 (1.33)	4.10 (1.51)	0.993
DLCO <sup>§</sup> (% predicted)	59.8 (19.9)	57.2 (18.3)	0.600

Categorical data is presented as count (percentage) and continuous data is presented as mean (standard deviation) or median (interquartile range) depending on distribution. Between group comparisons were made using chi-square test, Fisher's exact test, unpaired T-test or Mann-Whitney U test as appropriate. <sup>†</sup>, Data missing for 5 patients in the responder group and 3 patients in the non-responder group; <sup>‡</sup>, Data missing for 3 patients in the responder group and 2 patient in the non-responder group; <sup>§</sup>, Data missing for 7 patients in the responder group and 5 patient in the non-responder group. CCI, Charlson's comorbidity index; CTD-ILD, connective tissue disease-related interstitial lung disease; DLCO, carbon monoxide diffusing capacity; FVC, forced vital capacity; GAP, gender, age, physiology; HRQL, health-related quality of life; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; mMRC, modified medical research council dyspnoea scale.

**Table S2** Health-related quality of life stratified into the GAP stages and ILD subgroups

Characteristics	Total population	IPF <sup>†</sup>	CTD-ILD <sup>‡</sup>	Other ILDs <sup>§</sup>
Sample size <sup>¶</sup>	94	27 (29%)	49 (52%)	18 (19%)
GAP stage I (n=63)				
EQ5D-3L				
Utility value	0.846 (0.212)	0.889 (0.281)	0.825 (0.196)	0.900 (0.216)
VAS	77.1 (12.3)	81.1 (6.5)	77.0 (12.5)	74.8 (14.8)
K-BILD				
Breathlessness & activities	57.4 (19.5)	57.4 (12.1)	56.5 (20.8)	60.6 (20.2)
Psychological	69.9 (17.7)	68.8 (15.2)	69.5 (18.2)	72.1 (18.8)
Chest symptoms	79.5 (16.0)	80.0 (15.4)	78.6 (15.8)	82.2 (18.3)
Total	66.7 (13.7)	66.3 (11.1)	66.3 (14.5)	68.4 (13.5)
GAP stage II (n=24)				
EQ5D-3L				
Utility value	0.838 (0.223)	0.915 (0.136)	0.788 (0.248)	0.640 (0.340)
VAS	74.5 (11.2)	74.5 (10.2)	77.3 (8.8)	70.0 (18.3)
K-BILD				
Breathlessness & activities	49.8 (19.4)	51.4 (17.1)	41.5 (17.8)	56.2 (29.8)
Psychological	65.2 (18.8)	66.4 (17.7)	64.7 (23.8)	62.0 (20.1)
Chest symptoms	78.1 (18.9)	82.5 (15.0)	77.8 (20.0)	62.9 (26.4)
Total	62.0 (14.0)	63.6 (13.8)	58.0 (12.0)	62.4 (20.2)
GAP stage III (n=7)				
EQ5D-3L				
Utility value	0.299 (0.570)	-0.058 (0.473)	1.000	0.661 (0.119)
VAS	60.7 (11.7)	57.5 (9.6)	80.0	57.5 (10.6)
K-BILD				
Breathlessness & activities	31.7 (10.0)	32.1 (7.9)	22.9	35.5 (17.8)
Psychological	46.1 (14.6)	41.6 (17.4)	43.8	56.1 (9.8)
Chest symptoms	48.7 (24.4)	45.4 (30.6)	32.1	63.7 (0)
Total	47.0 (9.5)	44.8 (10.7)	42.4	53.7 (8.3)

All values reported as mean (standard deviation) or number (frequency) unless otherwise stated. There was no significant difference of the HRQL measures between the various ILD subtypes using IPF as a reference group. <sup>†</sup>, There were 9 patients in GAP stage I, 14 patients in GAP stage II, 4 patients in GAP stage III; <sup>‡</sup>, There were 42 patients in GAP stage I, 6 patients in GAP stage II, 1 patient in GAP stage III; <sup>§</sup>, There were 12 patients in GAP stage I, 4 patients in GAP stage II, 2 patients in GAP stage III; <sup>¶</sup>, Data missing for 2 patients for CTD-ILD and 3 patients for other ILDs. CTD-ILD, connective tissue disease-related interstitial lung disease; EQ5D-3L, EuroQol 5-dimension 3 level version; GAP, gender, age, physiology; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; K-BILD, King's brief interstitial lung disease Questionnaire; VAS, visual analogue scale.